Executive Summary

A novel class of agents for the treatment of retinal disease demonstrating:

  • Statistically significant improvement in LL-Visual Acuity indicating improved retinal function.
  • Significant reduction of GA lesion expansion.
  • No evidence of sustained increase in IOP or cataractogenisis.
  • No evidence of refractility.
  • Quarterly dosing materially reducing treatment burden.
  • Patents granted in over 30 countries for its use in Dry-AMD and GA.